Avelox in Complicated Skin and Skin Structure Infections
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This international, prospective, non-interventional, non-controlled observational study
obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life
treatment conditions. Specifically investigated are the improvement of clinical symptoms and
the duration until infection improvement and cure.Any patient with a diagnosis of complicated
skin and skin structure infection (cSSSI) treated with Avelox can be documented. The
observation period for each subject covers the treatment period with Avelox. For each
patient, the physician documents data at an initial visit and one or two follow-up visit(s)
in line with routine practice.
Details
Lead Sponsor:
Bayer
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination